FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510065326> ?p ?o ?g. }

• W2510065326 endingPage "e0004926" @default.
• W2510065326 startingPage "e0004926" @default.
• W2510065326 abstract "Typhoid persists as a major cause of global morbidity. While several licensed vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable for use in children less than two years of age. Development of new efficacious vaccines is complicated by the human host-restriction of Salmonella enterica serovar Typhi (S. Typhi) and lack of clear correlates of protection. In this study, we aimed to evaluate the protective efficacy of a single dose of the oral vaccine candidate, M01ZH09, in susceptible volunteers by direct typhoid challenge.We performed a randomised, double-blind, placebo-controlled trial in healthy adult participants at a single centre in Oxford (UK). Participants were allocated to receive one dose of double-blinded M01ZH09 or placebo or 3-doses of open-label Ty21a. Twenty-eight days after vaccination, participants were challenged with 104CFU S. Typhi Quailes strain. The efficacy of M01ZH09 compared with placebo (primary outcome) was assessed as the percentage of participants reaching pre-defined endpoints constituting typhoid diagnosis (fever and/or bacteraemia) during the 14 days after challenge. Ninety-nine participants were randomised to receive M01ZH09 (n = 33), placebo (n = 33) or 3-doses of Ty21a (n = 33). After challenge, typhoid was diagnosed in 18/31 (58.1% [95% CI 39.1 to 75.5]) M01ZH09, 20/30 (66.7% [47.2 to 87.2]) placebo, and 13/30 (43.3% [25.5 to 62.6]) Ty21a vaccine recipients. Vaccine efficacy (VE) for one dose of M01ZH09 was 13% [95% CI -29 to 41] and 35% [-5 to 60] for 3-doses of Ty21a. Retrospective multivariable analyses demonstrated that pre-existing anti-Vi antibody significantly reduced susceptibility to infection after challenge; a 1 log increase in anti-Vi IgG resulting in a 71% decrease in the hazard ratio of typhoid diagnosis ([95% CI 30 to 88%], p = 0.006) during the 14 day challenge period. Limitations to the study included the requirement to limit the challenge period prior to treatment to 2 weeks, the intensity of the study procedures and the high challenge dose used resulting in a stringent model.Despite successfully demonstrating the use of a human challenge study to directly evaluate vaccine efficacy, a single-dose M01ZH09 failed to demonstrate significant protection after challenge with virulent Salmonella Typhi in this model. Anti-Vi antibody detected prior to vaccination played a major role in outcome after challenge.ClinicalTrials.gov (NCT01405521) and EudraCT (number 2011-000381-35)." @default.
• W2510065326 created "2016-09-16" @default.
• W2510065326 creator A5000713282 @default.
• W2510065326 creator A5001567609 @default.
• W2510065326 creator A5002000465 @default.
• W2510065326 creator A5005135751 @default.
• W2510065326 creator A5014946608 @default.
• W2510065326 creator A5015402059 @default.
• W2510065326 creator A5023032597 @default.
• W2510065326 creator A5024501463 @default.
• W2510065326 creator A5028192637 @default.
• W2510065326 creator A5032122956 @default.
• W2510065326 creator A5036500915 @default.
• W2510065326 creator A5042729050 @default.
• W2510065326 creator A5045695482 @default.
• W2510065326 creator A5049145301 @default.
• W2510065326 creator A5053039384 @default.
• W2510065326 creator A5059715703 @default.
• W2510065326 creator A5061528291 @default.
• W2510065326 creator A5065914659 @default.
• W2510065326 creator A5073282795 @default.
• W2510065326 creator A5076688133 @default.
• W2510065326 creator A5082847955 @default.
• W2510065326 creator A5085081570 @default.
• W2510065326 creator A5090057576 @default.
• W2510065326 date "2016-08-17" @default.
• W2510065326 modified "2023-10-12" @default.
• W2510065326 title "Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a" @default.
• W2510065326 cites W1540445377 @default.
• W2510065326 cites W1971657493 @default.
• W2510065326 cites W1977861122 @default.
• W2510065326 cites W2003602243 @default.
• W2510065326 cites W2005813574 @default.
• W2510065326 cites W2006687695 @default.
• W2510065326 cites W2035255586 @default.
• W2510065326 cites W2051558015 @default.
• W2510065326 cites W2053020792 @default.
• W2510065326 cites W2058749640 @default.
• W2510065326 cites W2070969909 @default.
• W2510065326 cites W2098909275 @default.
• W2510065326 cites W2102898060 @default.
• W2510065326 cites W2104487243 @default.
• W2510065326 cites W2110513298 @default.
• W2510065326 cites W2111761743 @default.
• W2510065326 cites W2123106908 @default.
• W2510065326 cites W2125065061 @default.
• W2510065326 cites W2138554365 @default.
• W2510065326 cites W2145188627 @default.
• W2510065326 cites W2146955434 @default.
• W2510065326 cites W2147278081 @default.
• W2510065326 cites W2150527785 @default.
• W2510065326 cites W2151222379 @default.
• W2510065326 cites W2165663498 @default.
• W2510065326 cites W2323053493 @default.
• W2510065326 cites W4250873783 @default.
• W2510065326 cites W4251041657 @default.
• W2510065326 doi "https://doi.org/10.1371/journal.pntd.0004926" @default.
• W2510065326 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4988630" @default.
• W2510065326 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27533046" @default.
• W2510065326 hasPublicationYear "2016" @default.
• W2510065326 type Work @default.
• W2510065326 sameAs 2510065326 @default.
• W2510065326 citedByCount "63" @default.
• W2510065326 countsByYear W25100653262017 @default.
• W2510065326 countsByYear W25100653262018 @default.
• W2510065326 countsByYear W25100653262019 @default.
• W2510065326 countsByYear W25100653262020 @default.
• W2510065326 countsByYear W25100653262021 @default.
• W2510065326 countsByYear W25100653262022 @default.
• W2510065326 countsByYear W25100653262023 @default.
• W2510065326 crossrefType "journal-article" @default.
• W2510065326 hasAuthorship W2510065326A5000713282 @default.
• W2510065326 hasAuthorship W2510065326A5001567609 @default.
• W2510065326 hasAuthorship W2510065326A5002000465 @default.
• W2510065326 hasAuthorship W2510065326A5005135751 @default.
• W2510065326 hasAuthorship W2510065326A5014946608 @default.
• W2510065326 hasAuthorship W2510065326A5015402059 @default.
• W2510065326 hasAuthorship W2510065326A5023032597 @default.
• W2510065326 hasAuthorship W2510065326A5024501463 @default.
• W2510065326 hasAuthorship W2510065326A5028192637 @default.
• W2510065326 hasAuthorship W2510065326A5032122956 @default.
• W2510065326 hasAuthorship W2510065326A5036500915 @default.
• W2510065326 hasAuthorship W2510065326A5042729050 @default.
• W2510065326 hasAuthorship W2510065326A5045695482 @default.
• W2510065326 hasAuthorship W2510065326A5049145301 @default.
• W2510065326 hasAuthorship W2510065326A5053039384 @default.
• W2510065326 hasAuthorship W2510065326A5059715703 @default.
• W2510065326 hasAuthorship W2510065326A5061528291 @default.
• W2510065326 hasAuthorship W2510065326A5065914659 @default.
• W2510065326 hasAuthorship W2510065326A5073282795 @default.
• W2510065326 hasAuthorship W2510065326A5076688133 @default.
• W2510065326 hasAuthorship W2510065326A5082847955 @default.
• W2510065326 hasAuthorship W2510065326A5085081570 @default.
• W2510065326 hasAuthorship W2510065326A5090057576 @default.
• W2510065326 hasBestOaLocation W25100653261 @default.
• W2510065326 hasConcept C104317684 @default.
• W2510065326 hasConcept C126322002 @default.
• W2510065326 hasConcept C142724271 @default.

• next